Philippines - English - FDA (Food And Drug Administration)

globo asiatico enterprises, inc.; distributor: globo asiatico enterprises, inc. - epoeitin alfa - solution for injection (iv/sc) - 4000 iu/ml

Philippines - English - FDA (Food And Drug Administration)

globo asiatico enterprises, inc. - epoeitin alfa (recombinant human erythgromycin) - solution for iv/sc injection - 2,000 iu/ml

Philippines - English - FDA (Food And Drug Administration)

globo asiatico enterprises, inc.; distributor: globo asiatico enterprises, inc. - epoeitin alfa - solution for injection (iv/sc) - 10,000 iu/ml

Philippines - English - FDA (Food And Drug Administration)

cdm marketing center; distributor: cdm marketing center - epoeitin alfa - solution for injection (iv/sc) - 4,000iu/ml

European Union - English - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. , treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).,

United States - English - NLM (National Library of Medicine)

vifor (international) inc. - methoxy polyethylene glycol-epoetin beta (unii: lr3uxn0193) (methoxy polyethylene glycol-epoetin beta - unii:lr3uxn0193) - methoxy polyethylene glycol-epoetin beta 30 ug in 0.3 ml - mircera is indicated for the treatment of anemia associated with chronic kidney disease (ckd) in: limitations of use mircera is not indicated and is not recommended: mircera has not been shown to improve symptoms, physical functioning, or health-related quality of life. mircera is contraindicated in patients with: risk summary available data from a small number of published case reports and postmarketing experience with mircera use in pregnancy are insufficient to identify a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. chronic kidney disease is associated with maternal and embryo-fetal risks (see clinical considerations) . in animal reproduction studies, administration of methoxy polyethylene glycol-epoetin beta to rats and rabbits during pregnancy and lactation adversely affected offspring at doses 17-fold and greater than the recommended human dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated populatio

Kenya - English - Pharmacy and Poisons Board

serum institute of india ltd. 212/2, hadapsar, pune 411 028, india. - epoetin alfa - solution for injection - repoitin 2000 (vial and pfs): 2000 iu/0.5 ml of… - other antianemic preparations

Kenya - English - Pharmacy and Poisons Board

serum instititute of india pvt. ltd. 212/2, hadapsar, pune- 411 028, india. - epoetin alfa - solution for injection - repoitin 4000 : 4000/ 1 ml of api per unit dose. - erythropoietin

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 5000 iu - injection, solution - excipient ingredients: sodium hydroxide; dilute hydrochloric acid; water for injections; monobasic sodium phosphate dihydrate; polysorbate 80; sodium chloride; glycine; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 3000 iu - injection, solution - excipient ingredients: polysorbate 80; monobasic sodium phosphate dihydrate; water for injections; glycine; dilute hydrochloric acid; sodium chloride; sodium hydroxide; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.